NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

NuCana plc (NCNA) Stock Analysis

NuCana plc (NCNA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

NCNA

$1.40

−$0.03 (−2.10%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NCNA with… →

NCNA Key Statistics

As of Sep 4, 2026
Trading
Open
$1.41
Previous Close
$1.43
Day's Range
1.38–1.42
52-Week Range
1.21–7.22
Volume
32.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.24
Valuation
Market Cap
$5.83M
P/E Ratio
0.02
EPS (ttm)Profit attributable to each share over the last twelve months.
66.63
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$29.35M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.16M
1-Year Return
−51.05%
Dividend and dates
Avg Volume
66.25K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NCNA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−61.11%
2025−98.49%
2024−83.92%
2023−55.15%
2022−72.27%
2021−46.99%
2020−26.39%
2019−57.93%
2018+43.42%
2017 (partial year)−37.40%

As of September 4, 2026.

NCNA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$29.35M—
2024$0.00−$19.00M—
2023$0.00−$27.63M—
2022$0.00−$32.02M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$20.83M−$29.35M—
2024$0.00—−$23.01M−$19.00M—
2023$0.00—−$31.13M−$27.63M—
2022$0.00—−$43.72M−$32.02M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NCNA Valuation vs Biotechnology Median

Median of 656 stocks
MetricNCNABiotechnology medianvs median
P/E0.0212.570.0x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values NuCana plc (NCNA) at $5.83M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 10 employees.

NCNA last closed at $1.40 on September 4, 2026. That is −$0.03 (−2.10%) against the previous close. Over the past 52 weeks the price has ranged from $1.21 to $7.22. The latest close sits 15.7% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $29.35M. Profit margin runs at 0%. Earnings per share on a trailing basis come to 66.63.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 0.02. That is 0 times the Biotechnology median of 12.57. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 2.24. Daily returns over the trailing 8 years annualize to a volatility of 153.32%. Over the trailing twelve months the price has returned −51.05%. Across 5 years the annualized return works out at −83.88%.

Growth & Income

No dividend is on file for NCNA.

2026 is still running; the price is −61.11% year to date. Across the complete calendar years on file, 2018 returned +43.42% and 2025 returned −98.49%. Of the 8 complete calendar years on file, 1 finished higher.

Peer Comparison

NuCana plc (NCNA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NuCana plc NCNA $5.83M 0.0
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. NuCana plc trades at a P/E of 0.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About NuCana plc

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.

Visit website →